Multiple inflection points are colliding that will force action on drug pricing in the U.S.

At the moment, Congress is busy: · They need to construct and pass the $3.5 trillion reconciliation package and give final approval to the bipartisan infrastructure bill. · The reconciliation package is where action on drug pricing will likely take place; the infrastructure bill is important because it delays the Trump administration’s rebate rule by three years and also includes the Refund Act—a new requirement for drug companies to refund Medicare for leftover medicine when vials contain more of a physician-administered drug than a patient needs. This impacts manufacturers that produce single-vial doses. The Biden administration is also kicking …

Read the source article at Global Healthcare Marketing Company
2021-09-16 09:00:00